Matutes E, Catovsky D
Academic Department of Haematology and Cytogenetics, Royal Marsden Hospital, London UK.
Leuk Lymphoma. 1994;13 Suppl 1:11-4. doi: 10.3109/10428199409052666.
We describe the value of three scoring systems for the characterisation of haemopoietic malignancies. One of the scorings was devised to disclose unusual cases of biphenotypic/mixed lineage acute leukemias and proved to be useful to distinguish such cases from those ALL or AML with aberrant expression of one or two markers of another lineage. The other two scorings aimed respectively: 1) to discriminate between B-CLL from all other B-cell disorders which evolve with leukemia and 2) distinguish between hairy cell leukaemia (HCL), HCL-variant and splenic lymphoma with villous lymphocytes, a group of B-cell diseases with circulating "hairy" lymphocytes. Findings derived from the application of the latter two scoring systems in a large number of cases demonstrated that both provide objective criteria to differentiate between the B-cell conditions studied and that no single marker considered in isolation allows the distinction between the various B-lymphoproliferative disorders.
我们描述了三种用于造血系统恶性肿瘤特征描述的评分系统的价值。其中一种评分系统旨在揭示双表型/混合谱系急性白血病的罕见病例,并被证明有助于将此类病例与那些具有另一谱系一两种标志物异常表达的急性淋巴细胞白血病(ALL)或急性髓细胞白血病(AML)区分开来。另外两种评分系统的目的分别是:1)区分慢性淋巴细胞白血病(B-CLL)与所有其他演变为白血病的B细胞疾病;2)区分毛细胞白血病(HCL)、变异型毛细胞白血病(HCL-variant)和伴绒毛状淋巴细胞的脾淋巴瘤,这是一组具有循环“毛状”淋巴细胞的B细胞疾病。在大量病例中应用后两种评分系统得出的结果表明,两者都为区分所研究的B细胞疾病提供了客观标准,而且单独考虑任何一个标志物都无法区分各种B淋巴细胞增殖性疾病。